Pat Killingsworth Pat Killingsworth

Oncology: November 2011 Supplement well worth a look…

Interested in doing a bit of “light reading” this weekend?  Then don’t access the following three links I have been saving since November!

Maybe you should just file these away for anytime you need a detailed anti-myeloma drug profile:

The Future of Treatment for Patients With Relapsed/Refractory Multiple Myeloma

Lots of in-depth information here about new proteasome inhibitors in the pipeline:

Current Advances in Novel Proteasome Inhibitor–Based Approaches to the Treatment of Relapsed/Refractory Multiple Myeloma

CLICK-HERE to access.

Next up:

Current Advances in Non–Proteasome Inhibitor–Based Approaches to the Treatment of Relapsed/Refractory Multiple Myeloma

CLICK-HERE to read all about thalidomide, Revlimid, pomalidomide and a number of other new novel therapy agents in the pipeline.

Finally, what does ingesting all of these chemotherapy agents do to our bodies?  What are the risks?

Treatment-Related Adverse Events in Patients With Relapsed/Refractory Multiple Myeloma

CLICK-HERE to read Washington University’s Dr. Raj systematically lay-out the possible side-effects associated with myeloma therapy.

This is an excellent series, sponsored by Cancer Network.  Well worth a look.

But enough about drugs and drug therapy.  Monday, our friend Danny will share more thoughts about how to help combat multiple myeloma by using sound nutrition, targeted supplementation and a healthy lifestyle.

Until then, feel good and keep smiling!   Pat